According to Future Market Insights, the global severe asthma treatment market is predicted to develop at a CAGR of 5.1% from 2023 to 2033. By 2033, the global market for severe asthma therapy is estimated to reach a value of US$ 36.18 billion. The discovery of biologics and other targeted medicines has transformed the treatment of severe asthma, offering hope and respite to millions of individuals throughout the world who suffer from the disease.
The introduction of biologic drugs is one of the most promising advancements in the treatment of severe asthma. Biologics are medications derived from living organisms that can be utilised to target specific immune system pathways that induce inflammation in the airways. In clinical trials, these drugs shown great efficacy and are increasingly being used to treat persons with severe asthma who do not react well to conventional therapy.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16760
Some of the most commonly used biologics for severe asthma treatment include omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. These medications are administered via subcutaneous injections or intravenous infusion and have been shown to reduce asthma exacerbations, improve lung function, and enhance overall quality of life in people with severe asthma.
Overall, the global severe asthma treatment market is expected to continue to grow in the coming years, as more people are diagnosed with severe asthma and new and innovative treatments become available.
Key Takeaways from the Market Study
- The severe asthma treatment market is estimated to grow at a 5.1% CAGR from 2023 to 2033.
- In 2023, the inhaled route of administration is estimated to account for 40% of the severe asthma therapy market.
- In 2023, North America is estimated to hold 45% of the market for severe asthma therapy.
- In 2023, Europe’s severe asthma treatment market is estimated to account for 39% of the total.
“Advancements in treatments along with innovation of treatment options is expected to favor the growth of the market in the upcoming years.” states an FMI analyst
Ask Us Your Questions About This Report@ https://www.futuremarketinsights.com/ask-question/rep-gb-16760
Competitive Landscape
Key players in the severe asthma treatment market are Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron Pharmaceutical, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion
- The discovery and sale of a biologic medicine named Nucala by GlaxoSmithKline has been one of the company’s most significant achievements to the treatment of severe asthma (mepolizumab). Nucala is an anti-IL-5 monoclonal antibody used to treat severe eosinophilic asthma, a kind of severe asthma marked by high eosinophil levels in the blood and airways.
- The creation and sale of a biologic medicine named Xolair has been Novartis’ most significant contribution to the treatment of severe asthma (omalizumab). Xolair is an anti-IgE monoclonal antibody used to treat severe allergic asthma, which is caused by allergens such as pollen, dust mites, and animal dander.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global severe asthma treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Buy Complete Report@ https://www.futuremarketinsights.com/checkout/16760
Key Segments Profiled in the Severe Asthma Treatment Industry Survey
Drug Class:
- Reslizumab
- Benralizumab
- Anti-inflammatory
Route of Administration:
- Oral
- Inhaled
- Intravenous
- Subcutaneous
Device Type:
- Dry powder inhalers
- Metered dose inhalers
- Soft mist inhalers
About the Healthcare at Future Market Insights
The healthcare domain team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 Billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs